How does the MAVRiC study determine the duration of therapy for patients based on their IGHV mutational status?
Patients with unmutated IGHV receive one year of therapy, while those with mutated IGHV receive two years of therapy
Patients with unmutated IGHV receive two years of therapy, while those with mutated IGHV receive one year of therapy
All patients receive a fixed duration of therapy regardless of their IGHV mutational status